Key insights
- Twist Bioscience President and COO sold $141,026 in stock to cover tax obligations, a mandated transaction not reflecting discretionary trading. While the company beat revenue expectations in its recent earnings report, EPS missed forecasts. A new licensing agreement for an antibody platform was secured. Despite the insider sale and mixed earnings, Guggenheim maintained a Buy rating, suggesting limited immediate negative impact on the stock.
Patrick John Finn, President and Chief Operating Officer of Twist Bioscience Corp (NASDAQ:TWST), sold shares of the company’s common stock on April 23, 2026. The transaction involved a total of 2,321 shares, valued at $141,026.
The shares were sold at a price of $60.761 per share. Following this transaction, Mr. Finn directly owns 281,808 shares of Twist Bioscience common stock. The stock currently trades at $61.10, near its 52-week high of $66.06, reflecting a remarkable 78% surge over the past six months and a 92% gain year-to-date.
The sale represents shares required to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by Twist Bioscience’s equity incentive plans, which require tax withholding obligations to be funded by a "sell to cover" transaction, and do not represent discretionary trades by Mr. Finn.According to InvestingPro analysis, the stock appears overvalued at current levels. For deeper insights, investors can access a comprehensive Pro Research Report covering TWST and 1,400+ other US equities on the platform.
In other recent news, Twist Bioscience reported its first-quarter earnings for fiscal year 2026, showing a revenue of $103.7 million, which exceeded forecasts by 2.96%. However, the company’s earnings per share (EPS) did not meet expectations, coming in at -$0.50 against a forecast of -$0.43. In a strategic move, Twist Bioscience has entered a licensing agreement with Invenra Inc. for the B-Body bispecific antibody platform, allowing Twist to expand its antibody discovery services. This agreement positions Twist as a co-exclusive provider of the platform alongside Invenra.
Additionally, at its 2026 Annual Meeting, Twist Bioscience shareholders approved the election of directors and executive compensation, representing approximately 91.81% of the company’s outstanding shares eligible to vote. Guggenheim has reiterated a Buy rating for Twist Bioscience, maintaining a price target of $55.00 following the announcement of Amazon’s new drug discovery platform, Amazon Bio Discovery. This platform partners with Twist Bioscience to synthesize and test lead candidates.
Jefferies also commented on Amazon’s Bio Discovery launch, highlighting its integration of computational design with wet-lab validation for drug discovery. These developments reflect Twist Bioscience’s ongoing efforts to enhance its offerings and collaborate with industry leaders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders know the market. The hard part is the moment — which stock, right now, at what price. Chart analysis handles that. Our Vision AI scans your charts, spots the pattern before it plays out, and hands you the complete setup: entry, exit, done in under 60 seconds. Investors are already reporting a high accuracy rate, even on penny stocks.